Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 88, Issue 1, Pages 57-74Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2013.03.001
Keywords
Induction therapy; Head and neck cancer; Sequential therapy; TPF; Cetuximab; Chemoradiotherapy
Categories
Funding
- Genentech
- Amgen
- Eli Lilly
- Bristol-Myers Squibb
Ask authors/readers for more resources
As a component of multimodal therapy in locally advanced head and neck cancer, induction chemotherapy represents a strategy to reduce tumor burden and target distant metastases prior to definitive treatment. Although the addition of taxanes to the cisplatin and 5-fluorouracil induction regimen (TPF) has greatly benefitted outcomes in comparison with PF alone, recent phase III trials have not shown a survival advantage for TPF induction followed by chemoradiotherapy vs. chemoradiotherapy alone. While these trials may have been underpowered to demonstrate a survival benefit, additional phase Ill trials are ongoing, with highly anticipated results. Next-generation sequential regimens that include targeted agents such as cetuximab are emerging as an approach to increase activity while decreasing toxicity. In addition, patient selection based on individual disease characteristics may identify ideal candidates for induction therapy. These developments may result in personalized therapeutic regimens that improve clinical outcomes. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available